摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

[5-(Benzyloxy)-2-chlorophenyl]methanol | 876300-70-8

中文名称
——
中文别名
——
英文名称
[5-(Benzyloxy)-2-chlorophenyl]methanol
英文别名
{2-chloro-5-[(phenylmethyl)oxy]phenyl}methanol;(5-(Benzyloxy)-2-chlorophenyl)methanol;(2-chloro-5-phenylmethoxyphenyl)methanol
[5-(Benzyloxy)-2-chlorophenyl]methanol化学式
CAS
876300-70-8
化学式
C14H13ClO2
mdl
——
分子量
248.709
InChiKey
JRFYTCBQVVUIAF-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3.1
  • 重原子数:
    17
  • 可旋转键数:
    4
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.14
  • 拓扑面积:
    29.5
  • 氢给体数:
    1
  • 氢受体数:
    2

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • Triazolopyridinylsulfanyl derivatives as p38 MAP kinase inhibitors
    申请人:Mathias Paul John
    公开号:US20060035922A1
    公开(公告)日:2006-02-16
    A compound of formula (I), or a pharmaceutically acceptable salt and/or solvate (including hydrate) thereof; and the use of a compound of formula (I) in the treatment of a TNF-mediated disease, disorder, or condition, or a p38-mediated disease, disorder, or condition, in particular the allergic and non-allergic airways diseases, more particularly obstructive or inflammatory airways diseases, preferably chronic obstructive pulmonary disease.
    公式(I)的化合物,或其药学上可接受的盐和/或溶剂合物(包括水合物);以及公式(I)的化合物在治疗TNF介导的疾病、疾病或症状,或p38介导的疾病、疾病或症状中的用途,特别是过敏和非过敏的呼吸道疾病,更特别是梗阻性或炎症性呼吸道疾病,最好是慢性阻塞性肺病。
  • Triazolopyridinylsulfanyl Derivatives As P38 Map Kinase Inhibitors
    申请人:Mathias John Paul
    公开号:US20090239899A1
    公开(公告)日:2009-09-24
    A compound of formula (I), or a pharmaceutical acceptable salt and/or solvate (including hydrate) thereof; and the use of a compound of formula (I) in the treatment of a TNF-mediated disease, disorder, or condition, or a p38-mediated disease, disorder, or condition, in particular the allergic and non-allergic airways diseases, more particularly obstructive or inflammatory airways diseases, preferably chronic obstructive pulmonary disease.
    公式(I)的化合物,或其药学上可接受的盐和/或溶剂(包括水合物);以及在治疗TNF介导的疾病,紊乱或状况,或p38介导的疾病,紊乱或状况中使用公式(I)的化合物,特别是过敏和非过敏的气道疾病,更特别是阻塞性或炎症性气道疾病,最好是慢性阻塞性肺病。
  • Triazolopyridine Compounds
    申请人:Lewthwaite Russell Andrew
    公开号:US20090012079A1
    公开(公告)日:2009-01-08
    A compound of formula (Ia): or a pharmaceutically acceptable salt and/or solvate (including hydrate) thereof, or a compound of formula (Ib): or a pharmaceutically acceptable salt and/or solvate (including hydrate) thereof, and the use of a compound of formula (Ia) or (Ib) in the treatment of a TNF-mediated disease, disorder, or condition, or a p38-mediated disease, disorder, or condition, in particular the allergic and non-allergic airway diseases, more particularly obstructive or inflammatory airways diseases, preferably chronic obstructive pulmonary disease.
    化合物式(Ia)的化合物:或其药学上可接受的盐和/或溶剂(包括水合物),或化合物式(Ib)的化合物:或其药学上可接受的盐和/或溶剂(包括水合物),以及化合物式(Ia)或(Ib)在治疗TNF介导的疾病、障碍或病况,或p38介导的疾病、障碍或病况中的应用,特别是过敏性和非过敏性呼吸道疾病,更具体地说是阻塞性或炎症性呼吸道疾病,优选慢性阻塞性肺疾病。
  • N-PYRAZOLYL CARBOXAMIDES AS CRAC CHANNEL INIHIBITORS
    申请人:Allen David George
    公开号:US20120053150A1
    公开(公告)日:2012-03-01
    The present invention relates to amide compounds, processes for their preparation, pharmaceutical compositions containing these compounds and to their use in the treatment of disorders, conditions or disorders such as allergic disorders, inflammatory disorders and disorders of the immune system.
    本发明涉及酰胺化合物、其制备方法、含有这些化合物的药物组合物以及它们在治疗过敏性疾病、炎症性疾病和免疫系统疾病等疾病、症状或障碍中的应用。
  • COMPOUNDS
    申请人:Gore Paul Martin
    公开号:US20100273744A1
    公开(公告)日:2010-10-28
    The present invention relates to amide compounds, processes for their preparation, pharmaceutical compositions containing these compounds and to their use in the treatment of disorders, conditions or disorders such as allergic disorders, inflammatory disorders and disorders of the immune system.
    本发明涉及酰胺化合物,其制备方法,含有这些化合物的药物组合物以及它们在治疗过敏性疾病、炎症性疾病和免疫系统疾病等疾病、症状或障碍中的应用。
查看更多